Hola, creo que es el nombre del ensayo.

Abatacept (CTLA4-Ig) for the treatment of relapsing, non-severe, granulomatosis with polyangiitis (Wegener's)

The ABROGATE study is a multicentre, randomised, double-blind placebo-controlled phase III trial, aiming to determine the efficacy of abatacept to reduce treatment failure rate in patients with relapsing non-severe GPA over 12 months.

- See more at: http://www.hra.nhs.uk/news/research-summaries/abrogate/#stha...

ABROGATE Trial Launched to Assess Abatacept for Nonsevere Granulomatosis with Polyangiitis

An exciting new study in granulomatosis with polyangiitis (Wegener’s) (GPA) has begun: The first sites in the Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe GPA (ABROGATE) trial recently opened to enrollment, with more to join later this year. This trial will be a multinational initiative conducted by the Vasculitis Clinical Research Consortium (VCRC) in partnership with the European Vasculitis Study Group (EUVAS) and other international collaborators.
An unmet need: Treatment of nonsevere GPA

By focusing on a treatment option for the management of nonsevere GPA, ABROGATE addresses an unmet therapeutic need. Despite advances in the treatment of GPA, 50 to 70 percent of patients continue to experience a disease relapse following successful remission induction.

https://consultqd.clevelandclinic.org/2015/10/abrogate-trial...